Abstract
Mpox, formerly monkeypox, is a viral zoonotic disease caused by the monkeypox virus (MPXV). MPXV, which is taxonomically divided into clade I and II, was declared a Public Health Emergency of International Concern for the second time in August 2024 due to rapid geographic expansion of clade I viruses including the newly identified clade Ib. With a unique set of genomic mutations and sustained human-to human transmission, clade Ib has rapidly spread throughout the eastern Democratic Republic of the Congo as well as neighboring non-endemic regions. Limited epidemiological data suggests clade Ib is less virulent than other clade I and clade II viruses. There currently is a lack of quantitated comparative genomic analyses to address potential zoonotic transmissibility and pathobiology between the two clades. Here we show MPXV clades I and II share a core genome composed of 68 protein-coding genes which are common in the genomes of other poxviruses such as camelpox, cowpox, and vaccinia. The first documented and all subsequential queried isolates of clade Ib featured the deletion of the OPG032 gene, which was found present in all queried clade Ia genomes. OPG032 encodes a vaccinia ortholog which encodes the vaccinia complement protein, an important virulence protein. The schism event in the genomic structure highlighted by an entire gene deletion suggests it plays an important role in the pathobiology of the novel clade Ib. We anticipate our results lay the groundwork for exploiting the genomic of elements of MPXV as potential targets for therapeutics development/repurposing, vaccine design, and molecular diagnostic expansion as well to uncover the viral diversity and function of MPXV.
Competing Interest Statement
The authors G.S.M, A.K., M.D., P.K, and D.J.K. are shareholders of the company BioForge Canada Limited. The authors declare the interests of the company had no impact in the study.
Funding Statement
This work was supported by awards from the Canadian Institutes of Health Research, the Mpox Rapid Research Funding initiative (CIHR MZ1 187236), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), and Dalhousie Medical Research Foundation (DJK). Research in the Archibald Lab is supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN- 2019-05058) and the Gordon and Betty Moore Foundation (GBMF5782). The genomes were generated through DRC national genomic surveillance activities which are supported by many initiatives such as Africa CDC Pathogen Genomics Initiative (Africa PGI) (grants BMGF-INV-018278, INV-033857, Saving Lives and Livelihoods program, and NU2HGH000077); AFROSCREEN project (grant agreement CZZ3209, coordinated by ANRS-MIE Maladies infectieuses emergentes in partnership with Institut de Recherche pour le Developpement [IRD] and Pasteur Institute) funded by Agence Francaise de Developpement; PANAFPOX project funded by ANRS-MIE; Belgian Directorate-General Development Cooperation and Humanitarian Aid and the Research Foundation, Flanders (FWO, grant number G096222 N to L.L.); Department of Defense, Defense Threat Reduction Agency, and Monkeypox Threat Reduction Network; USDA Non-Assistance Cooperative Agreement #20230048; International mpox Research Consortium (IMReC), through funding from the Canadian Institutes of Health Research and International Development Research Centre (grant no. MRR-184813); and E.K.-L. received a PhD grant from the French Foreign Office.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
